LifeStance Health Group delivered a robust performance in the second quarter of 2025, with revenue increasing by 11% to $345.3 million. The company significantly reduced its net loss from $23.3 million in Q2 2024 to $3.8 million in Q2 2025, and saw a 19% increase in Adjusted EBITDA to $34.0 million. The clinician base expanded by 11% to 7,708, contributing to a 12% rise in visit volumes.

LifeStance Health Group, Inc. announced strong first quarter 2025 results, with revenue increasing 11% to $333.0 million and achieving a net income of $0.7 million, a significant improvement from a net loss in the prior year. The company also saw a 10% increase in its clinician base and visit volumes, contributing to its financial performance.

LifeStance Health Group reported a 16% increase in fourth-quarter revenue, reaching $325.5 million. The company's clinician base grew by 12% to 7,424, with visit volumes increasing by 14% to 2.0 million. Net loss for the quarter was $7.1 million, while net cash from operations was $62.3 million. Adjusted EBITDA stood at $32.8 million, and free cash flow was $56.0 million.

LifeStance Health Group reported a 19% increase in revenue to $312.7 million for Q3 2024. The company's net loss significantly improved to $6.0 million, and Adjusted EBITDA increased by 110% to $30.7 million. LifeStance also raised its full-year 2024 revenue and Adjusted EBITDA expectations.

LifeStance Health Group reported a 20% increase in revenue to $312.3 million for Q2 2024. The company's net loss decreased from $45.5 million to $23.3 million. Adjusted EBITDA increased 103% to $28.6 million. The company is raising full year 2024 revenue expectations to $1.2 billion to $1.242 billion and expects positive Free Cash Flow.

LifeStance Health Group reported a 19% increase in revenue to $300.4 million for Q1 2024. The clinician base grew by 15% to 6,866. The company is reiterating its full-year revenue guidance of $1.19 billion to $1.24 billion and raising its Adjusted EBITDA expectations to $88 to $98 million.

LifeStance Health Group, Inc. announced its Q4 2023 financial results, featuring a 22% increase in revenue to $280.6 million. The company's clinician base grew by 18%, with visit volumes up by 20%. Despite a net loss of $45.0 million, adjusted EBITDA was positive at $20.3 million. The company is focused on operational improvements and profitable growth.

LifeStance Health Group reported a 21% increase in total revenue, reaching $262.9 million. The company experienced a net loss of $61.6 million, influenced by stock-based compensation expenses and a preliminarily approved settlement. The company is raising the midpoints of full year Revenue, Center Margin, and Adjusted EBITDA guidance ranges.

LifeStance Health Group reported a 24% increase in total revenue to $259.6 million for Q2 2023. The company's net loss was $45.5 million, driven by stock-based compensation expense. The company is raising full year revenue and Center Margin guidance, with the following outlook for 2023: expects full year revenue of $1.01 to $1.04 billion, Center Margin of $280 to $300 million, and Adjusted EBITDA of $50 to $62 million.

LifeStance Health Group reported a 24% increase in total revenue to $252.6 million for Q1 2023. The company's net loss was $34.2 million, an improvement compared to the prior year's $62.3 million. The company is raising full year revenue and Center Margin guidance while reaffirming full year Adjusted EBITDA guidance.

LifeStance Health Group, Inc. reported a 21% increase in fourth-quarter revenue to $229.4 million. The company's clinician base grew by 18% to 5,631, with 200 net clinician additions in the fourth quarter. The company is focused on streamlining and standardizing its business to pave the way for profitable and sustainable growth.

LifeStance Health Group, Inc. announced its Q3 2022 financial results, with revenue reaching $217.6 million, a 25% increase compared to the previous year. The company reported a net loss of $37.9 million, which was impacted by stock-based compensation expenses. The company is shifting its focus to organic growth and profitability.

LifeStance Health Group reported a 31% increase in revenue to $209.5 million. The company's net loss was $68.7 million, and Adjusted EBITDA was $14.6 million. The company is expecting full year 2022 revenue and Center Margin toward the bottom end of the previously guided ranges of $865 million to $885 million and $240 million to $255 million, respectively, due to refined clinician seasonality assumptions; reaffirming Adjusted EBITDA guidance of $63 million to $67 million.

LifeStance Health Group, Inc. reported revenue of $203.1 million, a 42% increase compared to the previous year. The company's clinician base grew by 51% to 4,989. Net loss was $62.3 million, primarily due to stock-based compensation expense. The company reaffirmed its full year 2022 revenue guidance of $865 million to $885 million.

LifeStance Health Group, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2021, with a 61% increase in fourth-quarter revenue to $190.1 million and a 55% increase in the clinician base to 4,790 clinicians.

LifeStance Health Group reported a 70% increase in revenue to $173.8 million for the third quarter of 2021, driven by a 72% increase in clinicians. However, the company experienced a net loss of $120.5 million, primarily due to stock and unit-based compensation. The company is adjusting its full-year revenue expectations to the lower end of the previously guided range due to anticipated clinician holiday time off.

LifeStance Health Group, Inc. reported a strong second quarter with a 91% increase in revenue compared to the previous year. The company successfully completed its IPO and is focused on expanding access to mental health care services, adding clinicians, and opening new centers.